Abstract 3328: Using Luminex approach to develop a panel of anti-TAA autoantibodies for the detection of prostate cancer

Abstract

Autoantibodies to tumor-associated antigens (TAAs) have been demonstrated as reporters in early carcinogenesis. Luminex technology enables the development of simultaneous detection of multiple autoantibodies. This study aimed to use Luminex technology to evaluate and develop an optimal panel for the detection of prostate cancer (PCa) based on autoantibodies to fourteen TAAs (p53, p16, IMP2, IMP3, SOX2, BIRC5, HIF1-α, HSP60, ENO1, CTAG1B, MUC1, Her2, GAL1, and GAL3) associated with cancers. A total of 163 samples including 91 PCa sera and 72 normal control sera were screened to evaluate the expression of fourteen autoantibodies by multiple autoantibody bead panel. Except for autoantibodies to Her2 and IMP3, twelve autoantibodies showed significantly high frequencies ranging from 19.8% to 51.6% in the PCa group at 95.8% specificity for normal controls. The area under the curve (AUC) of these twelve autoantibodies ranged from 0.609 to 0.868. After logistic regression modeling and leave-one-out cross-validation, an optimal panel with the combination of three autoantibodies to p16, IMP2, and HSP60 was developed, achieving an AUC of 0.909 with 71.4% sensitivity and 95.8% specificity. Autoantibody to HSP60 exhibiting the best performance with an AUC of 0.868 in the autoantibody bead panel was further validated by Enzyme-linked immunosorbent assay (ELISA) with a larger size sample containing 200 PCa sera and 137 normal control sera, it also showed an AUC of 0.848 to identify PCa from normal controls. Therefore, the autoantibody bead panel showed similar results to ELISA. In summary, we developed an optimal autoantibody bead-based panel for the detection of PCa. It could be used as a high throughput tool to facilitate Pca detection. Citation Format: Cuipeng Qiu, Xiao Wang, Serina Batson, Giulio Francia, Jian-Ying Zhang. Using Luminex approach to develop a panel of anti-TAA autoantibodies for the detection of prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3328.